Recent Updates
Recently added Catalysts

Immutep Limited

IMMPFDA catalysts, PDUFA dates & pipeline intelligence
$3.26
▼ -0.14 · -4.12%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IMMP financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $2.6652W HIGH $70.60
Volume
6.83 K
Value Traded
22.20 K
Short % Float
0.45%
Days to Cover
2.4
-8.43%Week
+2.84%1 Month
-58.56%3 Month
-65.18%6 Month
-89.55%5 Year
-98.96%All Time

Cash Data

Unlock IMMP cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
24.03 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
7.37 M
Float Shares
7.31 M
Insiders
0.84%
Institutions
0.97%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data presentation
eftilagimod alfa (efti) plus pembrolizumab and radiotherapy
resectable soft tissue sarcoma (neoadjuvant)
Orphan
Phase 2BiologicsOncology
Unlock every IMMP catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IMMP Catalyst Timeline

Dated clinical, regulatory and corporate events for Immutep Limited

Catalyst Timeline

Dated clinical, regulatory & corporate events for Immutep Limited

1419Total events
14Upcoming
262Tier-1 (high impact)
2012 to 2029Coverage

Upcoming catalysts 2

T3Poster Presentation
Subscribe to view catalyst details
eftilagimod alfa (efti / IMP321)Filed
T2Timing Guidance
Subscribe to view catalyst details
eftilagimod alfa (efti / IMP321)Filed

Event history 50

▲Abstracteftilagimod alfa (efti / IMP321)FiledPresentation
CTOS 2026 abstract released with first survival data from EFTISARC-NEO
resectable soft tissue sarcomasource ↗
▲Secondary Endpoint Dataeftilagimod alfa (efti / IMP321)FiledClinical Data
Interim 12-month DFS/LRFS/DMFS data reported from EFTISARC-NEO
resectable soft tissue sarcomasource ↗
▲Patent Grantedeftilagimod alfa (efti / IMP321)FiledIP / Competition
USPTO granted US patent 12,788,796 covering efti plus PD-1 pathway inhibitor combinations
▲PK PD DataIMP761Clinical Data
Statistically significant, exposure-dependent inhibition of T-cell-driven immune responses with IMP761
autoimmune diseasessource ↗
▲Late-BreakerIMP761Presentation
Late-breaking abstract at ACR Convergence 2026 reports positive Phase I IMP761 data
autoimmune diseasessource ↗
▲Poster PresentationIMP761Presentation
Poster presentation of IMP761 Phase I data at ACR Convergence 2026
autoimmune diseasessource ↗
▲Preclinical PoCIMP761Preclinical
IMP761 reduced T-cell activation and proliferation in rheumatoid arthritis patient samples
rheumatoid arthritissource ↗
▲Safety Data UpdateIMP761Clinical Data
No new safety signals in ongoing MAD portion of Phase I IMP761 study
autoimmune diseasessource ↗
▲Grant / FundingCorporate
€1.36 million Crédit d'Impôt Recherche payment received from French Government
▲Secondary Endpoint Dataeftilagimod alfa (efti / IMP321)FiledClinical Data
HRQoL data show stable QoL during treatment and significant improvement after surgery
resectable soft tissue sarcomasource ↗
Unlock the full IMMP catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IMMP actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-10IMP761 Phase 1 data presentation Phase 1
Unlock 11 more IMMP historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 14%
Micro Cap
(rank 102 of 725)
Percentile Rank
Showing 10 of 12 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
eftilagimod alfa (efti / IMP321) BiologicsNCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 3 ACTIVE NOT_RECRUITING 756Sep 1, 2029
IMP321 BiologicsCompletedNCT02614833Adenocarcinoma Breast Stage IVPhase 2 COMPLETED 242May 1, 2021
eftilagimod alfa (efti / IMP321) BiologicsCompletedNCT03625323NSCLCPhase 2 COMPLETED 187Nov 25, 2024
eftilagimod alfa (efti / IMP321) BiologicsCompletedNCT04811027HNSCCPhase 2 COMPLETED 171Nov 5, 2025
IMP321 BiologicsCompletedNCT00349934Metastatic Breast CancerPhase 1 COMPLETED 33Jan 1, 2010
IMP321 BiologicsCompletedNCT00351949Stage IV Renal Cell CarcinomaPhase 1 COMPLETED 24Oct 1, 2008
IMP321 Small MoleculesCompletedNCT02676869Stage IV MelanomaPhase 1 COMPLETED 24Dec 1, 2019
IMP761 BiologicsCompletedNCT06637865UndisclosedPhase 1 COMPLETED 79Aug 27, 2026
Cvac BiologicsMarketedNCT01068509Epithelial Ovarian CancerApproved COMPLETED 63Apr 1, 2015
MUC1 Dendritic Cell Vaccine VaccinesMarketedNCT01617629Epithelial Ovarian CancerApproved COMPLETED 9Apr 1, 2014
Unlock the IMMP pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every IMMP program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
IMP761 Phase 12026-11-08statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers; well tolerated across all seven dose levels; no serious or severe adverse events reportedRead MoreIMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune ResponsesRead More
Scroll for more · summaries link to the source press release
Unlock every IMMP trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IMMP insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
No insider trades match the selected filters.
Unlock the full IMMP insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Boxer Capital Management, LLC 0.3 % 9.68 M 2.50 M
Unlock every fund holding IMMP
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IMMP
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IMMP ownership
Insider and institutional ownership, quarter by quarter.

IMMP Short Interest

Shares sold short, counted twice a month.

0.45%
Short % of Float
of tradable shares sold short
33.2K
Shares Sold Short
-1.1% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
13.9K
Avg Daily Volume
the average used for days to cover
Unlock IMMP short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock IMMP option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IMMP option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IMMP options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IMMP ranks across every disease it competes in

Competitive Position is a premium feature
See how IMMP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IMMP News

IMMP
Nov 10, 2026
IMMPGeneral

Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

Immutep Limited announced the grant of a new US patent for efti-based combination therapies, expanding its patent portfolio to five patents. The new patent covers combinations of efti with PD-1 pathway inhibitors, enhancing its protection in cancer treatment. CEO Marc Voigt emphasized the strategic importance of this patent for future development opportunities.

Read more →
IMMP
Nov 10, 2026
IMMPPhases

Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO

Immutep announced preliminary survival data from the EFTISARC-NEO trial, showing promising outcomes for patients with resectable soft tissue sarcoma. The study reported 12-month disease-free survival rates of 81.1%, local recurrence-free survival at 94.1%, and distant metastasis-free survival at 86.2%. Further analyses will be presented at the CTOS 2026 Annual Meeting.

Read more →
IMMP
Nov 8, 2026
IMMPPhases
▲ +13.8%on this newsshared move

IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

Immutep Limited announced positive results from its Phase I study of IMP761, showing significant inhibition of T-cell-driven immune responses in healthy volunteers. The drug was well tolerated across all doses, and the ongoing study has not revealed new safety concerns. Results from the multiple ascending dose portion are expected in H1 CY2027.

Read more →
IMMP
Nov 5, 2026
IMMPConferences/Events
▼ -8.8%on this newsshared move

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Immutep Limited announced upcoming poster presentations for its MHC Class II agonist, eftilagimod alfa, at CTOS 2026 and ESMO 2026. The presentations will include survival data from the EFTISARC-NEO Phase II trial and final median overall survival results from the TACTI-003 Phase IIb trial. These events will take place in November and December 2026.

Read more →
IMMP
Oct 29, 2026
IMMPGeneral

Immutep Quarterly Activities Report Q1 FY27

Immutep Limited reported its Q1 FY27 activities, focusing on the registration-directed development of efti for HNSCC and STS. The EFTISARC-NEO trial showed promising results, while the TACTI-004 study was discontinued due to unexpected outcomes. The company maintains a strong cash position, with funding expected to last into H1 CY28.

Read more →
IMMP
Oct 28, 2026
IMMPGeneral
▲ +5.4%on this newsshared move

Immutep Receives A$2.16 million French R&D Tax Incentive

Immutep Limited announced it received A$2.16 million from the French Government under the CIR tax incentive for R&D activities in 2025. This funding will support its ongoing research for product candidates eftilagimod alfa and IMP761. The company also received a cash rebate from the Australian Government and is eligible for Germany's R&D tax incentive.

Read more →
IMMP
Oct 23, 2026
IMMPPhases

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Immutep presented quality of life data from the EFTISARC-NEO Phase II trial at ESMO 2026. The trial evaluated efti in combination with pembrolizumab and radiotherapy for soft tissue sarcoma. Results showed stable quality of life during treatment and significant improvements in patient-reported outcomes after surgery. Efti's safety profile supports its use in combination therapies.

Read more →
IMMP
Oct 19, 2026
IMMPConferences/Events

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

Immutep Limited announced that a late-breaking abstract on IMP761 has been accepted for poster presentation at ACR Convergence 2026. The poster will showcase data from a Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, conducted in healthy volunteers. The study aims to evaluate the drug's immunosuppressive effects and its potential in treating autoimmune diseases.

Read more →
IMMP
Oct 14, 2026
IMMPGeneral
▼ -5.3%on this newsshared move

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

Immutep Limited has announced that Monash University received a grant of A$652,248 from the Australian Research Council to support ongoing research into LAG-3. This funding will enhance their collaboration, which has previously led to significant findings regarding LAG-3's role in immune response regulation. The project aims to further explore LAG-3's interactions and its therapeutic potential.

Read more →
IMMP
Oct 13, 2026
IMMPFDA Updates

Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement

Immutep Limited has received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement. The company's American Depositary Shares (ADSs) traded above $1.00 for 10 consecutive business days, resolving a previous deficiency. This compliance is crucial for maintaining its listing on the Nasdaq Global Market.

Read more →
IMMP
Sep 30, 2026
IMMPGeneral

Immutep Receives ~A$0.86 Million R&D Tax Incentive

Immutep Limited has secured an A$856,669 cash rebate from the Australian government's R&D tax incentive program for eligible activities in the 2025 fiscal year. The company is also eligible for R&D tax incentives in France and Germany, which will support its ongoing research into product candidates efti and IMP761. However, the timing and amount of future payments remain uncertain due to regulatory processes.

Read more →
IMMP
Sep 21, 2026
IMMPGeneral

Change to American Depositary Share Ratio

Immutep Limited announced a change in the ratio of its American Depositary Shares (ADSs) from 1:10 to 1:200, effective September 28, 2026. This adjustment is a strategic move to comply with Nasdaq's minimum bid price requirement after the ADSs traded below $1.00 for 30 consecutive days. The change does not impact the number of ordinary shares or the company’s capital structure.

Read more →
IMMP
Sep 11, 2026
IMMPPhases
▲ +14.8%on this news

Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)

Immutep Limited has outlined a focused development strategy for eftilagimod alfa, targeting head and neck squamous cell carcinoma and soft tissue sarcoma. The company has contracted a new manufacturing run to address issues identified in the TACTI-004 study. Preparations for future clinical trials are underway, with a targeted start in the second half of 2027.

Read more →
IMMP
Jul 30, 2026
IMMPPhases

Immutep Quarterly Activities Report Q4 FY26

Immutep Limited reported positive developments in its quarterly activities for Q4 FY26, highlighting a pooled analysis of efti trials that demonstrated a 7.7-month survival benefit. The company also shared promising results from its IMP761 trial, while addressing the discontinuation of the TACTI-004 trial due to futility. Financially, Immutep remains strong with significant cash reserves.

Read more →
IMMP
Jul 24, 2026
IMMPConferences/Events

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

Immutep Limited announced that an abstract for the EFTISARC-NEO Phase II trial has been accepted for presentation at the ESMO Congress 2026 in Madrid. The abstract will feature health-related quality of life data regarding their first-in-class MHC Class II agonist, eftilagimod alfa. The full abstract will be published on the ESMO website on October 19, 2026.

Read more →
IMMP
Jul 14, 2026
IMMPGeneral

Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor

Immutep Limited has secured a fourth U.S. patent for its immunotherapy, eftilagimod alfa, which is designed for cancer treatment in combination with PD-1 pathway inhibitors. This new patent enhances the company's intellectual property portfolio, supporting future development and business opportunities. Eftilagimod alfa is currently being evaluated for various solid tumors and has received Fast Track designation from the FDA.

Read more →
IMMP
Jul 13, 2026
IMMPPhases
▲ +7.5%on this newsshared move

Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004

Immutep announced positive results from the INSIGHT-003 Phase I trial, showing a median overall survival of 30.9 months in patients with non-squamous NSCLC. The results are particularly encouraging for patients with low PD-L1 expression, who typically have fewer treatment options. However, the TACTI-004 trial was discontinued after a futility analysis indicated inferior outcomes compared to the control arm.

Read more →
IMMP
Jun 4, 2026
IMMPPhases

Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026

Immutep Limited announced positive interim Phase I data for its LAG-3 agonist antibody, IMP761, which showed favorable safety and pharmacodynamic activity in healthy volunteers. The study met its primary endpoint and demonstrated significant immunosuppressive effects, supporting further clinical investigation in autoimmune diseases. Additional updates are expected in H2 CY2026.

Read more →
IMMP
May 28, 2026
IMMPPhases

Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients

Immutep Limited announced positive results from five clinical trials evaluating eftilagimod alfa in late-stage cancer patients. The combination of eftilagimod alfa with standard-of-care therapies led to a significant increase in overall survival, particularly among patients showing an immune response. The findings suggest a strong link between immune activation and improved clinical outcomes across various cancer types.

Read more →
IMMP
May 1, 2026
IMMPPhases
▼ -5.6%on this news

Immutep Quarterly Activities Report & Appendix 4C Q3 FY26

Immutep has decided to discontinue the TACTI-004 Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer based on a recommendation from the Independent Data Monitoring Committee. The interim futility analysis indicated that patients receiving the treatment were underperforming compared to those on a placebo. Although this outcome was disappointing, Immutep continues to explore other avenues for its clinical programs, including ongoing trials like INSIGHT-003, which show favorable results. The company's financial position remains solid with a cash balance of approximately A$110.6 million.

Read more →

About Immutep Limited

46 employees immutep.com
BIOPHARMAWATCH ELITE
Trade the next IMMP catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime